Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 11/20 | 0.52 |
| ▸ | MAPK13 | O15264 | 10/20 | 0.52 |
| ▸ | MAPK12 | P53778 | 10/20 | 0.52 |
| ▸ | MAPK11 | Q15759 | 10/20 | 0.52 |
| ▸ | MAPK9 | P45984 | 3/20 | 0.51 |
| ▸ | IDH1 | O75874 | 4/20 | 0.48 |
| ▸ | LCK | P06239 | 3/20 | 0.47 |
| ▸ | FLT1 | P17948 | 1/20 | 0.46 |
| ▸ | FLT4 | P35916 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7590696 | 1.00 | MAPK14 (0.52) | MAPK14MAPK13MAPK12MAPK11MAPK9 | |
| SCHEMBL7528721 | 0.91 | MAPK14 (0.54) | MAPK14MAPK13MAPK12MAPK11MAPK9 | |
| SCHEMBL7665202 | 0.90 | MAPK14 (0.51) | MAPK14MAPK13MAPK12MAPK11MAPK9 | |
| SCHEMBL7665192 | 0.90 | MAPK14 (0.51) | MAPK14MAPK13MAPK12MAPK11MAPK9 | |
| SCHEMBL7664862 | 0.88 | LCK (0.54) | IDH1LCK | |
| SCHEMBL7664856 | 0.88 | LCK (0.54) | IDH1LCK | |
| SCHEMBL7671470 | 0.86 | MAPK14 (0.55) | MAPK14MAPK13MAPK12MAPK11MAPK9 | |
| SCHEMBL7686135 | 0.85 | MAPK14 (0.49) | MAPK14MAPK13MAPK12MAPK11MAPK9 | |
| SCHEMBL7667059 | 0.82 | MAPK14 (0.46) | MAPK14MAPK13MAPK12MAPK11MAPK9 | |
| SCHEMBL7671628 | 0.82 | MAPK14 (0.56) | MAPK14MAPK13MAPK12MAPK11MAPK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6492516-B1 | PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF WHICH EXHIBIT UTILITY FOR THE TREATMENT OF CYTOKINE MEDIATED DISEASES SUCH AS ARTHRITIS. | MERCK & CO., INC. | 2002-12-10 | — | — | US | disclosed |
| EP-1180101-A4 | COMPOUNDS HAVING CYTOKINE INHIBITORY ACTIVITY | MERCK & CO INC (US) | 2002-08-28 | — | — | EP | disclosed |
| EP-1180101-A1 | COMPOUNDS HAVING CYTOKINE INHIBITORY ACTIVITY | Merck & Co., Inc. (US) | 2002-02-20 | — | — | EP | disclosed |
| WO-2000069848-A1 | COMPOUNDS HAVING CYTOKINE INHIBITORY ACTIVITY | MERCK & CO., INC. (US) | 2000-11-23 | — | — | WO | disclosed |